For the second time in a year, Pharmstandard turned out to be the only pharmaceutical company that made a bid for supplying rilpivirine + tenofovir + emtricitabine, a three-component antiretroviral medication included in the list of vital and essential drugs (VED List).
As a result, the company will be awarded a contract for the supply of Gilead-manufactured Eviplera worth 777.88 million rubles. Pharmstandard will supply 884,958 tablets of Eviplera to the Ministry of Health at a maximum initial price of 879 rubles per tablet, with the expiration date not earlier than May 2019.
The Ministry of Health will provide the drug to 77 Russian regions, the Federal Medical and Biological Agency (FMBA), and to the institutions of the Federal Penitentiary Service. The largest amount of tablets (156 thousand) will be provided to the Ministry of Health of the Moscow region. The medicines must be supplied by December 1, 2018.
The combined form of rilpivirine + tenofovir + emtricitabine is included in the VED List since September 2015. According to 2018 data, its procurement is made only by the Ministry of Health and the Department of Health of Moscow.